Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study

Al B. Benson, Jean Francois Geschwind, Mary F. Mulcahy, William Rilling, Gary Siskin, Greg Wiseman, James Cunningham, Bonny Houghton, Mason Ross, Khairuddin Memon, James Andrews, Chad J. Fleming, Joseph Herman, Halla Nimeiri, Robert J. Lewandowski, Riad Salem*

*Corresponding author for this work

Research output: Contribution to journalArticle

52 Scopus citations

Abstract

Purpose To investigate the safety, response rate, progression-free and overall survival of patients with liver metastases treated with 90Y (glass) radioembolisation in a prospective, multicenter phase II study. Methods 151 patients with liver metastases (colorectal n = 61, neuroendocrine n = 43 and other tumour types n = 47) refractory to standard of care therapies were enrolled in this prospective, multicenter, phase II study under an investigational device exemption. Clinical/laboratory/imaging follow-up were obtained at 30 days followed by 3-month intervals for 1 year and every 6 months thereafter. The primary end-point was progression-free survival (PFS); secondary end-points included safety, hepatic progression-free survival (HPFS), response rate and overall survival. Results Median age was 66 (range 25-88). Grade 3/4 adverse events included pain (12.8%), elevated alkaline phospatase (8.1%), hyperbilirubinemia (5.3%), lymphopaenia (4.1%), ascites (3.4%) and vomiting (3.4%). Treatment parameters including dose delivery were reproducible among centers. Disease control rates were 59%, 93% and 63% for colorectal, neuroendocrine and other primaries, respectively. Median PFS was 2.9 and 2.8 months for colorectal and other primaries, respectively. PFS was not achieved in the neuroendocrine group. Median survival from 90Y treatment was 8.8 months for colorectal and 10.4 months for other primaries. Median survival for neuroendocrine patients has not been reached. Conclusion Patients with liver metastases can be safely treated with 90Y microspheres. This study is the first to demonstrate technical and dose reproducibility of 90Y glass microspheres between centers in a prospective setting. Based on these promising data, three international, multicenter, randomised phase III studies in colorectal and hepatocellular carcinoma have been initiated.

Original languageEnglish (US)
Pages (from-to)3122-3130
Number of pages9
JournalEuropean Journal of Cancer
Volume49
Issue number15
DOIs
StatePublished - Oct 1 2013

    Fingerprint

Keywords

  • Chemotherapy
  • Liver metastases
  • Progressive disease
  • Radioembolisation
  • TheraSphere
  • Yttrium-90

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Benson, A. B., Geschwind, J. F., Mulcahy, M. F., Rilling, W., Siskin, G., Wiseman, G., Cunningham, J., Houghton, B., Ross, M., Memon, K., Andrews, J., Fleming, C. J., Herman, J., Nimeiri, H., Lewandowski, R. J., & Salem, R. (2013). Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study. European Journal of Cancer, 49(15), 3122-3130. https://doi.org/10.1016/j.ejca.2013.05.012